Search clinical trials for: Recombinant Interleukin-2

Total 18641 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Anal Cancer | Gallbladder Cancer

United States
Peking University People's Hospital

Completed

Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis

Relapsing Polychondritis

China
Peking University People's Hospital

Enrolling by invitation

Interleukin-2 on Active Dermatomyositis

Dermatomyositis

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

Sarcoma | Lymphoma | Kidney Cancer | Testicular Germ Cell Tumor | Breast Cancer | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma

United States
University of Washington
Merck Sharp & Dohme LLC; Prometheus Laboratories

Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
Second Xiangya Hospital of Central South University

Recruiting

Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris

Pemphigus Vulgaris

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

Recurrent Merkel Cell Carcinoma | Stage IV Merkel Cell Carcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Peking University People's Hospital

Recruiting

Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome

Sjögren's Syndrome

China
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Clear Cell Tumor | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian... and other conditions
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Stage IV Melanoma

United States
Beijing VDJBio Co., LTD.

Recruiting

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Idiopathic Multicentric Castleman's Disease

China
University Hospital, Bordeaux

Completed

Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (ANEMIL)

Autoimmune Hemolytic Anemia

France
NYU Langone Health
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Continuous Infusion of rhIL-15 for Adults With Advanced Cancer

Lymphoma | Carcinoma

United States
The First Hospital of Jilin University

Completed

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura (HSP)

Purpura, Schoenlein-Henoch

China
Zhejiang Cancer Hospital

Unknown

Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis

Nasopharyngeal Carcinoma

China
Shanghai Children's Medical Center
Xiamen Amoytop Biotech Co., Ltd.

Completed

Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

Pancytopenia Due to Chemotherapy

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating rhIL-11 in Active Crohn's Disease

Crohn Disease | Inflammatory Bowel Disease

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Virginia Commonwealth University
American Heart Association

Completed

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

Heart Failure

United States
Revimmune
Washington University School of Medicine; University Hospital, Limoges; George...

Terminated

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-C&D)

Sepsis, Severe

United States, France
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) (SILCAAT)

HIV Infection

United States
University of Michigan Rogel Cancer Center
University of Michigan

Terminated

Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine

Metastatic Colorectal Cancer

United States
Loma Linda University

Withdrawn

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Melanoma | Metastatic Kidney Cancer

United States
Celularity Incorporated

Terminated

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
NCIC Clinical Trials Group
ZymoGenetics

Completed

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Melanoma (Skin)

Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network

Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone

United States
University of Pittsburgh
Wyeth is now a wholly owned subsidiary of Pfizer; University of North Carolina

Completed

Phase II Study of IL-11 (Neumega) in Von Willebrand Disease

Von Willebrand Disease

United States
Chiron Corporation

Completed

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

Lymphoma, Non-Hodgkin

United States
Weill Medical College of Cornell University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

Hepatitis C

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low-dose Interleukin-2 in Women With Unexplained Miscarriages (FaCIL-2)

Recurrent Miscarriage

France
Mayo Clinic

Completed

Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

Posterior Cortical Atrophy (PCA) | Atypical Alzheimers Disease | Logopenic Variant of Primary Progressive Aphasia (LPA)

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN

Systemic Lupus Erythematosus | Lupus Nephritis

China
Chiron Corporation

Completed

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Lymphoma, Non-Hodgkin

United States
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline

Completed

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)

COVID-19

Honduras, United States, Australia, France, New Zealand, Spain, United Kingdom
National Cancer Institute (NCI)

Completed

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

Sarcoma | Neuroblastoma | Solid Tumors | Brain Tumors | Pediatric Cancers

United States
Liaoning Tumor Hospital & Institute

Completed

To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment

Chemotherapy-induced Thrombocytopenia

China
French National Agency for Research on AIDS and...
Chiron Corporation

Completed

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

HIV Infections

France
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Ultra Low Dose Interleukin-2 in Healthy Volunteers

Hematologic Diseases

United States
Indiana University School of Medicine
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix

Cervical Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Leukemia | Chronic | Lymphocytic | B-Cell

United States

Search clinical trials for: Recombinant Interleukin-2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations